Ulcerative Colitis & IBD By GutFeel Editorial Team

Entyvio (Vedolizumab) Effectiveness + Side Effects

Entyvio (Vedolizumab) Effectiveness + Side Effects: How Entyvio Works and How Effective Is Entyvio for Ulcerative Colitis.

Researched and written by the GutFeel Editorial Team. Not medically reviewed and not medical advice — how we write these guides.

medication

Key Takeaways

  • Gut-Selective Mechanism: Entyvio (vedolizumab) is a humanized monoclonal antibody that targets α4β7 integrin, selectively blocking gut-homing lymphocytes from entering the intestinal lining to reduce localized inflammation.
  • Phase 3 Trial Efficacy: In the GEMINI 1 study, 41.8–44.8% of patients remained in clinical remission at 1 year on Entyvio versus 15.9% on placebo, with over 50% achieving endoscopic mucosal healing.
  • Systemic Safety Profile: Because its action is gut-selective, Entyvio generally demonstrates a favorable systemic safety profile compared to systemic anti-TNF agents.
  • Administration: Administered via IV infusion (300 mg at weeks 0, 2, and 6, then every 8 weeks) or subcutaneous maintenance injection where approved.
  • Common Side Effects: Includes nasopharyngitis, headache, joint pain, nausea, fever, and upper respiratory tract infections.

How Entyvio Works: The Gut-Selective Advantage

Unlike systemic immunosuppressants that block inflammatory signals throughout the entire body, Entyvio (vedolizumab) functions as a gut-selective integrin antagonist:

  1. Targeting α4β7 Integrin: Vedolizumab binds specifically to the α4β7 integrin receptor expressed on circulating gut-homing T-lymphocytes.
  2. Preventing Mucosal Migration: By blocking the interaction with MAdCAM-1 endothelial receptors on intestinal blood vessels, Entyvio prevents inflammatory white blood cells from infiltrating the gut mucosa.
  3. Preserving Systemic Immunity: Because MAdCAM-1 is predominantly expressed in the GI tract, systemic immune function remains largely uninhibited, reducing systemic infection risks.

How Effective Is Entyvio for Ulcerative Colitis?

Clinical Trial Evidence (GEMINI 1)

In the landmark phase 3 GEMINI 1 study in adults with moderate to severe active ulcerative colitis:

  • Week 6 Induction: Significantly higher clinical response (47.1% vs. 25.5%) and clinical remission (16.9% vs. 5.4%) compared to placebo.
  • Week 52 Maintenance: 41.8% of patients receiving 300 mg every 8 weeks and 44.8% receiving 300 mg every 4 weeks achieved sustained clinical remission versus 15.9% on placebo.
  • Mucosal Healing: 51.6–56.0% achieved endoscopic mucosal healing at 1 year versus 19.8% on placebo.
  • Deep Remission: Over 40% achieved composite symptomatic and endoscopic deep remission at 52 weeks.

Real-World Effectiveness

Real-world observational studies confirm Entyvio’s durability:

  • High maintenance persistence rates over 1 to 3 years of therapy.
  • Effective both in bio-naïve patients and those who previously failed anti-TNF biologics (infliximab, adalimumab).

Dosing Schedule & Route of Administration

  • Intravenous (IV) Induction: 300 mg infused over 30 minutes at Week 0, Week 2, and Week 6.
  • Maintenance Dosing: 300 mg IV every 8 weeks. Patients with incomplete response may be adjusted to every 4 weeks.
  • Subcutaneous Option: Where regulatory approvals permit, subcutaneous 108 mg pre-filled pens may be used for maintenance following IV induction.

Side Effects & Safety Profile

Common Side Effects

  • Nasopharyngitis, sore throat, and sinus infections
  • Headache and joint pain (arthralgia)
  • Nausea and abdominal discomfort
  • Fatigue, fever, and mild rash

Serious Risks & Monitoring

  • Infusion Reactions: Mild to moderate acute infusion reactions (hypersensitivity) occur in a small percentage of patients.
  • Infection Monitoring: While systemic risks are low, serious localized infections can occur. Pre-treatment screening for TB and viral hepatitis is standard.
  • PML Risk: Progressive multifocal leukoencephalopathy (PML) is a theoretical concern associated with integrin inhibitors; however, zero cases of PML directly attributed to Entyvio have been observed in UC clinical trial registries.

How Quickly Does Entyvio Work?

  • Entyvio is recognized for a gradual onset compared to systemic anti-TNFs or oral JAK inhibitors.
  • Initial symptom improvements usually appear between weeks 6 and 14.
  • Clinical guidelines advise continuing therapy through week 14 before declaring primary non-response, as mucosal healing continues to accumulate over the first 6 to 12 months.

Related Clinical & Diagnostic Resources

References

  1. Feagan BG, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis (GEMINI 1). N Engl J Med. 2013;369(8):699-710.
  2. Sands BE, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis (VARSITY). N Engl J Med. 2019.

Want help spotting your own food triggers?

GutFeel.ai scans meals and packaged foods for high-FODMAP ingredients and tracks which ones line up with your symptoms.

Take the free 60-second assessment →